Atrial Fibrillation Trial, Recruiting NCT04997824 Sponsor: Yonsei University Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT04997824
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose left atrium (one of the heart's chambers) measures less than 55 mm in size
  • People whose irregular heart rhythm (atrial fibrillation) has come back even while taking heart rhythm medications, or who cannot tolerate those medications
  • People for whom a doctor has determined that blood-thinning (anticoagulant) therapy is appropriate to help prevent blood clots

Who may not be able to join:

  • People whose atrial fibrillation is linked to serious heart structural problems or heart defects that affect how the heart pumps blood
  • People who have difficulty undergoing a CT scan that uses contrast dye (a special liquid used to make images clearer)
  • People who currently have active internal bleeding
  • People for whom blood-thinning therapy is not considered appropriate
  • People with serious additional health conditions (confirm with trial site for specific details)
  • People who are not expected to survive beyond one year
  • People with a current addiction to drugs or alcohol
  • People who are unable to read and understand the consent form (for example, due to literacy or language barriers)
  • People who the trial investigators determine are not suitable for participation for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hui-Nam Pak, Severance Hospital, Yonsei University Health System

Phone: 82-2-2228-8459

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 October 2021
Est. completion
1 June 2031

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Efficacy of Atrial Fibrillation Catheter Ablation(AFCA); safety of Atrial Fibrillation Catheter Ablation(AFCA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov